For the long-term observation of disease progression of patients with no residual tumor burden, it became evident that a high status was significantly (p = 0.018) associated with an inferior 10-year PFS, with a median survival time of 27 ± 13.4 month (HR: 2.7, 95% CI: 1.3–10.1; Figure 5), compared to a low status of vesicular-bound HLA-G with a median survival time of 68 ± 25.6 months. This evidence concerns the gene HLA-G and neoplasm.